Bone turnover markers are correlated with total skeletal uptake of 99mTc-methylene diphosphonate (99mTc-MDP)
© Lenora et al; licensee BioMed Central Ltd. 2009
Received: 21 November 2008
Accepted: 30 March 2009
Published: 30 March 2009
Skeletal uptake of 99mTc labelled methylene diphosphonate (99mTc-MDP) is used for producing images of pathological bone uptake due to its incorporation to the sites of active bone turnover. This study was done to validate bone turnover markers using total skeletal uptake (TSU) of 99mTc-MDP.
22 postmenopausal women (52–80 years) volunteered to participate. Scintigraphy was performed by injecting 520 MBq of 99mTc-MDP and taking whole body images after 3 minutes, and 5 hours. TSU was calculated from these two images by taking into account the urinary loss and soft tissue uptake. Bone turnover markers used were bone specific alkaline phosphatase (S-Bone ALP), three different assays for serum osteocalcin (OC), tartrate resistant acid phosphatase 5b (S-TRACP5b), serum C-terminal cross-linked telopeptides of type I collagen (S-CTX-I) and three assays for urinary osteocalcin (U-OC).
The median TSU of 99mTc-MDP was 23% of the administered activity. All bone turnover markers were significantly correlated with TSU with r-values from 0.52 (p = 0.013) to 0.90 (p < 0.001). The two resorption markers had numerically higher correlations (S-TRACP5b r = 0.90, S-CTX-I r = 0.80) than the formation markers (S-Total OC r = 0.72, S-Bone ALP r = 0.66), but the difference was not statistically significant. TSU did not correlate with age, weight, body mass index or bone mineral density.
In conclusion, bone turnover markers are strongly correlated with total skeletal uptake of 99mTc-MDP. There were no significant differences in correlations for bone formation and resorption markers. This should be due to the coupling between formation and resorption.
Bone metabolism can be assessed by biochemical means using bone turnover markers (BTM) measured in serum or urine . BTMs can be used in the monitoring of antiresorptive therapy [2, 3] and there is increasing evidence that at least some BTMs can be predictive for bone loss  and fracture [5, 6]. They are, however, also subjected to rapid changes due to reasons other than bone metabolism , such as diurnal variation, other tissue damages and food intake . Some of the BTMs reflect bone formation, while others are associated to bone resorption. However, both formation and resorption markers are usually affected by changes in turnover due to the coupling between these two processes .
Several attempts have been made to assess the skeletal metabolic activity by using skeletal uptake of radiolabelled, bone seeking, substances. Bisphosphonates, structurally similar to the inorganic pyrophosphates in bone matrix, have high affinity to bind to bone mineral . Especially, they bind to the exposed sites that undergo high bone turnover. Technetium-99m (99mTc) labelled diphosphonates are commonly used in scintigraphic uptake studies to detect lesions in conditions such as cancer metastasis, occult fractures and osteomyelitis due to their high affinity to metabolically active sites in bone. In these procedures the skeletal or extra-osseous accumulation of 99mTc labelled methylene diphosphonate (99mTc-MDP) is used to identify the lesions as "hot spots" [10, 11]. In earlier studies the measurement of 24-hour whole body retention of 99mTc-MDP was used to assess the skeletal metabolism [12, 13], before introducing the regional quantification of 99mTc-MDP activity by D'Addabbo et al  and Brenner et al . These techniques have been found to be useful techniques for estimating skeletal turnover rate at the time of the measurement. The regional quantification after 5-hours has the advantage over 24-hour retention that it directly gives a measure of skeletal uptake and a shorter time period is needed. To the best of our knowledge, the correlation between bone metabolism assessed by skeletal uptake of 99mTc-MDP and by bone turnover markers has been evaluated only in a few studies [13, 16–18].
This study was designed to assess the correlation between the skeletal uptake of 99mTc-MDP, and nine bone turnover markers including markers of bone formation and bone resorption and urinary osteocalcin. Our aim was to elucidate if markers reflect total skeletal turnover determined by skeletal uptake of 99mTc-MDP. Furthermore, we aimed to investigate if uptake of 99mTc-MDP is more related to bone formation or resorption, assuming that if any of the bone formation markers had a significantly greater correlation with TSU, over the others; it could have been regarded as a relatively specific measure of bone formation.
22 postmenopausal women who had sought medical advice or treatment for minor orthopaedic complains (such as non-fracture trauma, back pain, vertebral fractures, ankle fractures) at least 6 months before the recruitment and who had never been treated with bisphosphonates were selected from the registers of the orthopaedic clinic at Malmö University Hospital. Patients with primary hyperparathyroidism, hyperthyroidism, osteomalacia, chronic malnutrition, any malignancy, hepatic cirrhosis, joint prosthesis; or patients who had been treated with systemic estrogens, therapeutic calcium, vitamin D or corticosteroids within the last one year were not included. When the study was started, they were free from the condition that had originally brought them to the clinic. Fractures within 2 years prior to the study were also recorded.
Bone mineral density
Areal bone mineral density (BMD) of total body, lumbar spine, femoral neck and bone mineral content (BMC) of the total body were measured by dual-energy x-ray absorptiometry (DXA) (Lunar DPX-L® Madison, USA). The precision of measurements assessed by duplicate measurements on 15 elderly women after repositioning were 0.5% for total body BMD, 1.3% for total body BMC, 1.2% for lumber spine BMD, and 3.9% for femoral neck BMD.
Bone scintigraphy procedure was performed within 28 days after the DXA scanning according to a method described by Brenner et al . An injection of 520 (517 ± 15) MBq of 99mTc-MDP (Medronate®, Amersham international) was given. The radio activity was measured in the syringe both before and after injection to enable an accurate determination of injected activity. Whole body imaging was performed directly (3 minutes) after injection and 5 hours after injection. A double-headed gamma camera system (Siemens Multispect 2) equipped with low energy high-resolution collimators was used for the scan. The scan speed was 40 cm/min for the image at 3 minutes and 15 cm/min for the image after 5 hours. The images were stored in a 1024 × 256 matrix for image processing.
Serum and urine samples for bone turnover markers
Non-fasting blood samples were collected before the scintigraphy procedure (at 9.00 am). Serum was separated within 2 hours after phlebotomy. Non-fasting urine samples were collected at 9.00 am. Serum and urine samples were stored at -80°C for the analysis of bone turnover markers.
Bone turnover markers
All the analyses were done at the same time. Bone-specific alkaline phosphatase (S-Bone ALP) was determined by using Metra BAP immunoassay (Quidel Corporation), with an intra- and inter- assay CV of 3.6% and 4.4%, respectively. Serum intact osteocalcin [S-OC(1–49)], serum total osteocalcin (S-Total OC) and serum total gamma-carboxylated osteocalcin (S-cOC) were determined by previously described, in-house protocols with intra- and inter- assay CV of less than 5% and 8%, respectively, for all the assays .
Serum C-terminal cross-linking telopeptides of type I collagen (S-CTX-I) were determined by Elecsys β-Cross Laps® immunoassay (Roche diagnostics) with intra- and inter- assay CV of 5.9% and 5.8%, respectively. Serum tartrate-resistant acid phosphatase 5b (S-TRACP5b) was assessed by a solid phase, immunofixed, enzyme activity assay as described earlier  with an intra- and inter- assay CV of 1.8% and 2.2%, respectively.
Three different assays of urinary osteocalcin, total osteocalcin (U-TotalOC), long osteocalcin (U-LongOC) and mid osteocalcin (U-MidOC) were analyzed as previously published with intra- and inter- assay CVs of 14% and < 27% (U-TotalOC), 4.3% and < 14% (U-LongOC), and 1.7% and < 12% (U-MidOC), respectively .
Urinary creatinine was measured by the kinetic Jaffe reaction with a Beckman synchron LX20-4, with CVs of 3% or less. All the measurements of urinary osteocalcin were corrected for urinary creatinine and expressed as ratios.
Statistica for Windows (version 7.1, Stat Soft Inc) software was used for the statistical analysis. The results were expressed as median and inter quartile range (IQR). The correlations of bone turnover markers and the total skeletal uptake of 99mTc-MDP were assessed by using Spearman rank correlations. Group comparisons were done using Mann-Whitney U test. P-values less than 0.05 were considered statistically significant.
All steps of the study were approved by the ethical review committee, Lund University, Sweden in accordance with the Declaration of Helsinki. Informed, consent was obtained from each of the participants prior to the study.
Baseline characteristics, scintigraphy results and bone turnover markers of participants (n = 22).
Median (inter quartile range)
Correlations with TSU of 99mTc-MDP
65 (59 – 73)
162 (158 – 167)
65 (60 – 79)
25.4 (22.8 – 29.1)
Total body BMC (g)
2075 (1933 – 2208)
Total body BMD (g/cm2)
1.02 (0.97 – 1.08)
Total skeletal uptake (%)
22.9 (18.8 – 27.9)
Bone Formation markers
S-Bone ALP (U/L)
23.0 (17.0 – 28.0)
S-Total OC (μg/L)
5.8 (5.0 – 8.5)
3.0 (2.2 – 5.0)
6.9 (5.4 – 9.1)
Bone resorption markers
3.1 (2.5 – 3.9)
228 (173 – 326)
U-Total OC/crea (μg/nmol)
28.3 (19.7 – 32.0)
U-Mid OC/crea (μg/nmol)
1.3 (0.9 – 2.0)
U-Long OC/crea (μg/nmol)
0.02 (0.01 – 0.04)
The median value for total skeletal uptake of 99mTc-MDP at 5 hours was 23% (IQR (18.8 – 27.9). There were no statistically significant associations between total skeletal uptake and total body BMD, total body BMC, body weight, BMI or age (Table 1).
Bone turnover markers
Comparison of women with and without a recent fracture
Baseline characteristics, BMD, scintigraphy results and bone turnover markers in women with and without a recent fracture.
Women with a recent fracture (n = 8)
Women without a recent fracture (n = 14)
62 (58 – 71)
66 (60 – 73)
163 (159 – 168)
162 (157 – 167)
64 (61 – 69)
68 (57 – 84)
24.2 (22.6 – 27.5)
26.5 (22.8 – 29.8)
Total body BMC (g)
1976 (1929 – 2051)
2127 (1960 – 2247)
Total body BMD (g/cm2)
0.97 (0.94 – 1.04)
1.04 (1.00 – 1.08)
Total skeletal uptake (%)
28.6 (21.3 – 31.8)
21.6 (17.0 – 24.8)
Bone formation Markers
S-Bone ALP (U/L)
27.0 (24.0 – 34.5)
21.0 (16.0 – 25.0)
S-Total OC (μg/L)
8.2 (5.5 – 13.3)
5.8 (4.4 – 7.3)
4.9 (3.0 – 10.0)
2.9 (2.1 – 4.4)
10.2 (6.6 – 16.5)
6.1 (5.3 – 7.8)
Bone resorption Markers
3.8 (2.9 – 5.2)
2.8 (2.4 – 3.7)
411 (186 – 639)
203 (173 – 253)
U-Total OC/crea (μg/nmol)
30.5 (27.0 – 32.1)
25.5 (17.4 – 29.8)
U-Mid OC/crea (μg/nmol)
1.9 (1.3 – 2.4)
1.1 (0.9 – 1.7)
U-Long OC/crea (μg/nmol)
0.03 (0.01 – 0.08)
0.02 (0.01 – 0.03)
Comparison of women with and without osteoporosis
There was no statistically significant difference in bone turnover markers or in total skeletal uptake of 99mTc-MDP between women with osteoporosis (n = 8) and other women (n = 14) (data not shown).
We have studied the association between nine bone turnover markers, representing different aspects of bone turnover, and total skeletal metabolism, as assessed by scintigraphic measurement of total skeletal uptake of 99mTc-MDP. All bone turnover markers were highly correlated to bone metabolism assessed by total skeletal uptake of 99mTc-MDP.
S-TRACP5b and S-CTX-I, the markers of bone resorption, were found to be numerically best correlated with TSU of 99mTc-MDP. The correlations for bone formation markers were, however, also highly significant and it was not evident which of the bone turnover markers were associated to total skeletal metabolism the most. Studies with 99mTc-MDP suggest that MDP uptake reflects a combination of skeletal blood flow and osteoblastic activity [22, 23]. However, markers of bone formation not seemed to be more correlated with such uptake than markers of bone resorption. The lack of difference between formation and resorption markers could be due to the coupling of these two processes. Moreover, studies with radio-labelled bisphosphonates have shown that bisphosphonates localize to regions where new bone is being deposited and newly formed crystals provide a surface area of exposed mineral available to adsorb bisphosphonates, but are also incorporated where osteoclasts are resorbing bone .
In addition, the precision and accuracy of the assays for bone turnover markers differ. These differences in assay performance may have influenced the correlations between bone markers and TSU of 99mTc-MDP, making the comparison of markers more difficult.
The highest r-value (0.90) was observed for S-TRACP5b. TRACP5b is an enzyme produced by bone-resorbing osteoclasts and the activity of TRACP5b in serum reflects the number of active osteoclasts [25, 26]. The r-value for S-CTX-I was almost as high (0.80) as for S-TRACP5b. CTX-I results from cathepsin K-mediated degradation of type I collagen by osteoclasts . The number of bone-resorbing osteoclasts (TRACP5b), as well as the amount of degraded type I collagen (CTX-I) should be tightly correlated to the rate of skeletal metabolism. The collection of samples at non-fasting status may, however, have interfered with the correlation for CTX-I, as it's levels are known to be influenced by food intake .
The r-values for formation markers S-OC and S-bone ALP were slightly lower (0.65 – 0.72). S-OC has a short half-life in circulation  and it may be more susceptible to preanalytical variability, such as in vitro degradation . Moreover, circulating OC may contain molecules derived from both formation and resorption processes . Bone-specific alkaline phosphatase is an enzyme originating from osteoblasts and needed in osteoid formation and mineralization. Although the methods currently available detect preferentially the bone-specific isoform of the enzyme, they still show a certain degree of cross-reactivity between bone and liver isoforms . The r-values for two of the three urinary OC assays were of similar magnitude (0.72 and 0.76) than for serum OC (0.65, 0.67 and 0.72).
Previous studies on healthy individuals, individuals with endocrine disorders (such as Cushing's syndrome, thyrotoxicosis and primary hyperparathyroidism) or other skeletal diseases (such as heterotrophic pulmonary ostoarthropathy) have shown TSU of 99mTc-MDP to be correlated to conventional bone turnover markers such as osteocalcin, urinary deoxypyridinoline , total alkaline phosphatase, and urinary hydroxyproline [13, 16–18] but data on many currently available, more specific and sensitive bone turnover markers has been lacking.
We did not detect correlation for TSU and age or for TSU and BMD. Previous studies on healthy women, have shown that the TSU of 99mTc-MDP is positively correlated with age (n = 40, 84) [16, 32] and negatively correlated with BMD (n = 86) . The absence of such correlation in our study may be due to limited sample size.
When the women who had sustained fractures within two years prior to the study were compared to the others, women with recent fracture had higher level of bone formation markers and higher level of TSU of 99mTc-MDP. This is in line with our previous findings that bone formation markers remains elevated up to 1–2 years after fracture [34, 35]. Only one out of eight women had visible focal uptake on the scintigram, on the site of prior fracture. Most probably the increase of bone turnover in the fractured individuals is due to the generalized post traumatic skeletal process taking place after fracture  as well local increase at the fracture site.
A main strength of this study is that we analyzed several BTMs reflecting different aspects of bone metabolism. In particular, the novel bone turnover markers such as S-TRACP5b and urinary osteocalcins have not been evaluated by using TSU of 99mTc-MDP in any of the earlier studies. There are also limitations. Small sample size hindered us to compare which of the BTMs that correlated most with TSU of 99mTc-MDP. This should be possible with larger sample sizes, including also samples for relatively high and low levels of formation and resorption, such as children, and patients on anabolic treatments (high bone formation rate), patients with osteolytic bone metastases (high bone resorption rate) or patients on anti-resorptive therapy (low bone formation and resorption rate). Another limitation was with the scanning of scintigraphic procedure used. When we take the whole body image at 3 min, with the speed of 40 cm/min, it took about 3 minutes for the camera to reach the thighs where soft tissue uptake was calculated. It was assumed that 100% of radioisotope is in soft tissue at this early image, but by this time (approximately 6 minutes) some of radioisotope could have already entered the skeleton or filtered by the kidneys. When the study was initiated, information on the effect of feeding on BTMs was not available. Samples were collected without fasting and the non-fasting status may have had minor influence on the results of a few markers, in particular S-CTX-I 
In conclusion, biochemical markers of bone turnover are strongly correlated with the skeletal metabolism as measured by TSU of 99mTc-MDP. Although 99mTc-MDP uptake is largely driven by osteoblastic activity, there were no significant differences in correlations between skeletal uptake of 99mTc-MDP and bone formation markers or bone resorption markers. This could be due to coupling between formation and resorption.
Technitum 99m labelled methyline diphosphonate
Total skeletal uptake
Areal bone mineral density
Bone mineral content
Dual energy x-ray absorptiometry
Inter quartile range
- S-Bone ALP:
Serum bone specific alkaline phosphatise
- S-Total OC:
Serum total osteocalcin
Serum intact osteocalcin
Serum carboxylated osteocalcin
Serum tartrate resistant acid phosphatase 5b
Serum C-terminal cross-linked telopeptides of type I collagen
- U-Total OC/crea:
Urinary total osteocalcin to urinary creatinine ratio
- U-Mid OC/crea:
Urinary mid osteocalcin to urinary creatinine ratio
- U-Long OC/crea:
Urinary long osteocalcin to urinary creatinine ratio.
This work received financial support from the Swedish Medical Research Council and the Helsingin Sanomain 100-vuotissäätiö Foundation, Finland.
- Watts NB: Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999, 45 (8 Pt 2): 1359-1368.PubMedGoogle Scholar
- Bonnick SL, Shulman L: Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006, 119 (4 Suppl 1): S25-31. 10.1016/j.amjmed.2005.12.020.View ArticlePubMedGoogle Scholar
- Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, et al: Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res. 2005, 20 (10): 1804-1812. 10.1359/JBMR.050403.View ArticlePubMedGoogle Scholar
- Lenora J, Ivaska KK, Obrant KJ, Gerdhem P: Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int. 2007, 18 (9): 1297-1305. 10.1007/s00198-007-0379-z.View ArticlePubMedGoogle Scholar
- Garnero P: Markers of bone turnover for the prediction of fracture risk. Osteoporos Int. 2000, 11 (Suppl 6): S55-65. 10.1007/s001980070006.View ArticlePubMedGoogle Scholar
- Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Åkesson K, Obrant KJ: Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res. 2004, 19 (3): 386-393. 10.1359/JBMR.0301244.View ArticlePubMedGoogle Scholar
- Hannon R, Eastell R: Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int. 2000, 11 (Suppl 6): S30-44. 10.1007/s001980070004.View ArticlePubMedGoogle Scholar
- Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R: Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone. 2002, 30 (6): 886-890. 10.1016/S8756-3282(02)00728-7.View ArticlePubMedGoogle Scholar
- Papapoulos SE: Bisphosphonate actions: physical chemistry revisited. Bone. 2006, 38 (5): 613-616. 10.1016/j.bone.2006.01.141.View ArticlePubMedGoogle Scholar
- Flores LG, Nagamachi S, Jinnouchi S, Ohnishi T, Futami S, Nakahara H, Tamura S: Relationship between extraosseous accumulation in bone scintigraphy with 99Tcm-HMDP and histopathology. Nucl Med Commun. 1998, 19 (4): 347-354. 10.1097/00006231-199804000-00009.View ArticlePubMedGoogle Scholar
- Sahin M, Basoglu T, Bernay I, Yapici O, Canbaz F, Yalin T: Evaluation of metastatic bone disease with pentavalent 99Tc(m)-dimercaptosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions. Nucl Med Commun. 2000, 21 (3): 251-258. 10.1097/00006231-200003000-00009.View ArticlePubMedGoogle Scholar
- Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR: The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978, 19 (3): 270-275.PubMedGoogle Scholar
- Thomsen K, Johansen J, Nilas L, Christiansen C: Whole body retention of 99mTc-diphosphonate. Relation to biochemical indices of bone turnover and to total body calcium. Eur J Nucl Med. 1987, 13 (1): 32-35. 10.1007/BF00252643.View ArticlePubMedGoogle Scholar
- D'Addabbo A, Rubini G, Mele M, Lauriero F: A new method for assessing 99Tcm-MDP bone uptake from a bone scan image: quantitative measurement of radioactivity in global skeletal regions of interest. Nucl Med Commun. 1992, 13 (1): 55-60. 10.1097/00006231-199201000-00010.View ArticlePubMedGoogle Scholar
- Brenner W, Bohuslavizki KH, Sieweke N, Tinnemeyer S, Clausen M, Henze E: Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med. 1997, 24 (10): 1284-1290. 10.1007/s002590050153.View ArticlePubMedGoogle Scholar
- Carnevale V, Frusciante V, Scillitani A, Modoni S, Pileri M, Chiodini I, Dicembrino F, Romagnoli E, Minisola S: Age-related changes in the global skeletal uptake of technetium-99m methylene diphosphonate in healthy women. Eur J Nucl Med. 1996, 23 (11): 1473-1477. 10.1007/BF01254471.View ArticlePubMedGoogle Scholar
- Minisola S, Pacitti MT, Romagnoli E, Rosso R, Carnevale V, Caravella P, Scillitani A, Dicembrino F: Clinical validation of a new immunoradiometric assay for intact human osteocalcin. Calcif Tissue Int. 1999, 64 (5): 365-369. 10.1007/PL00005815.View ArticlePubMedGoogle Scholar
- Scillitani A, Dicembrino F, Chiodini I, Minisola S, Fusilli S, Di Giorgio A, Garrubba M, D'Aloiso L, Frusciante V, Torlontano M, et al: Global skeletal uptake of 99mTc-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover. Osteoporos Int. 2002, 13 (10): 829-834. 10.1007/s001980200115.View ArticlePubMedGoogle Scholar
- Käkönen SM, Hellman J, Karp M, Laaksonen P, Obrant KJ, Väänänen HK, Lövgren T, Pettersson K: Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum. Clin Chem. 2000, 46 (3): 332-337.PubMedGoogle Scholar
- Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res. 2000, 15 (7): 1337-1345. 10.1359/jbmr.2000.15.7.1337.View ArticlePubMedGoogle Scholar
- Ivaska KK, Kakonen SM, Gerdhem P, Obrant KJ, Pettersson K, Väänänen HK: Urinary osteocalcin as a marker of bone metabolism. Clin Chem. 2005, 51 (3): 618-628. 10.1373/clinchem.2004.043901.View ArticlePubMedGoogle Scholar
- Moore AE, Blake GM, Fogelman I: Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling. J Nucl Med. 2008, 49 (3): 375-382. 10.2967/jnumed.107.048595.View ArticlePubMedGoogle Scholar
- Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I: Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001, 31 (1): 28-49. 10.1053/snuc.2001.18742.View ArticlePubMedGoogle Scholar
- Masarachia P, Weinreb M, Balena R, Rodan GA: Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 1996, 19 (3): 281-290. 10.1016/8756-3282(96)00182-2.View ArticlePubMedGoogle Scholar
- Alatalo SL, Halleen JM, Hentunen TA, Monkkonen J, Väänänen HK: Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem. 2000, 46 (11): 1751-1754.PubMedGoogle Scholar
- Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM: Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem. 2004, 50 (5): 883-890. 10.1373/clinchem.2003.029355.View ArticlePubMedGoogle Scholar
- Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM: The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. 2003, 18 (5): 859-867. 10.1359/jbmr.2003.18.5.859.View ArticlePubMedGoogle Scholar
- Price PA, Williamson MK, Lothringer JW: Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981, 256 (24): 12760-12766.PubMedGoogle Scholar
- Garnero P, Grimaux M, Seguin P, Delmas PD: Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 1994, 9 (2): 255-264.View ArticlePubMedGoogle Scholar
- Ivaska KK, Hentunen TA, Vääräniemi J, Ylipahkala H, Pettersson K, Väänänen HK: Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem. 2004, 279 (18): 18361-18369. 10.1074/jbc.M314324200.View ArticlePubMedGoogle Scholar
- Seibel MJ: Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int. 2000, 11 (Suppl 6): S18-29. 10.1007/s001980070003.View ArticlePubMedGoogle Scholar
- Carnevale V, Dicembrino F, Frusciante V, Chiodini I, Minisola S, Scillitani A: Different patterns of global and regional skeletal uptake of 99mTc-methylene diphosphonate with age: relevance to the pathogenesis of bone loss. J Nucl Med. 2000, 41 (9): 1478-1483.PubMedGoogle Scholar
- Kigami Y, Yamamoto I, Ohnishi H, Takada M, Matsushita R, Hamanaka Y, Ota T, Morita R: Relationship between skeletal uptake of 99mTc-HMDP and bone mineral density in elderly women. Ann Nucl Med. 1998, 12 (1): 15-20.View ArticlePubMedGoogle Scholar
- Obrant KJ, Ivaska KK, Gerdhem P, Alatalo SL, Pettersson K, Väänänen HK: Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone. 2005, 36 (5): 786-792. 10.1016/j.bone.2005.02.009.View ArticlePubMedGoogle Scholar
- Ivaska KK, Gerdhem P, Åkesson K, Garnero P, Obrant KJ: Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res. 2007, 22 (8): 1155-1164. 10.1359/jbmr.070505.View ArticlePubMedGoogle Scholar
- Obrant KJ, Nilsson BE: Histomorphologic changes in the tibial epiphysis after diaphyseal fracture. Clin Orthop Relat Res. 1984, 270-275. 185
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1756-6649/9/3/prepub